135 related articles for article (PubMed ID: 19108985)
1. Hierarchical modeling gave plausible estimates of associations between metabolic syndrome and components of antiretroviral therapy.
Young J; Glass TR; Bernasconi E; Rickenbach M; Furrer H; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC;
J Clin Epidemiol; 2009 Jun; 62(6):632-41. PubMed ID: 19108985
[TBL] [Abstract][Full Text] [Related]
2. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study.
Young J; Rickenbach M; Weber R; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
Antivir Ther; 2005; 10(1):73-81. PubMed ID: 15751765
[TBL] [Abstract][Full Text] [Related]
3. Class of antiretroviral drugs and the risk of myocardial infarction.
; Friis-Møller N; Reiss P; Sabin CA; Weber R; Monforte Ad; El-Sadr W; Thiébaut R; De Wit S; Kirk O; Fontas E; Law MG; Phillips A; Lundgren JD
N Engl J Med; 2007 Apr; 356(17):1723-35. PubMed ID: 17460226
[TBL] [Abstract][Full Text] [Related]
4. The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study.
Smith CJ; Olsen CH; Mocroft A; Viard JP; Staszewski S; Panos G; Staub T; Blaxhult A; Vetter N; Lundgren JD
AIDS; 2008 Jan; 22(1):47-56. PubMed ID: 18090391
[TBL] [Abstract][Full Text] [Related]
5. Stavudine in antiretroviral therapy: is this the end?
Brinkman K
AIDS; 2009 Aug; 23(13):1727-9. PubMed ID: 19571724
[No Abstract] [Full Text] [Related]
6. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen.
Colafigli M; Di Giambenedetto S; Bracciale L; Tamburrini E; Cauda R; De Luca A
HIV Med; 2008 Mar; 9(3):172-9. PubMed ID: 18217998
[TBL] [Abstract][Full Text] [Related]
8. Fanconi syndrome and lactic acidosis associated with stavudine and lamivudine therapy.
Nelson M; Azwa A; Sokwala A; Harania RS; Stebbing J
AIDS; 2008 Jul; 22(11):1374-6. PubMed ID: 18580619
[TBL] [Abstract][Full Text] [Related]
9. Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir.
Gianotti N; Guffanti M; Galli L; Margonato A; Chiaravalli G; Bigoloni A; Lazzarin A; Castagna A
AIDS; 2007 Jul; 21(12):1648-51. PubMed ID: 17630564
[TBL] [Abstract][Full Text] [Related]
10. Severe hyperlactataemia complicating stavudine first-line antiretroviral therapy in South Africa.
Stead D; Osler M; Boulle A; Rebe K; Meintjes G
Antivir Ther; 2008; 13(7):937-43. PubMed ID: 19043928
[TBL] [Abstract][Full Text] [Related]
11. The metabolic syndrome: news from the 4th International AIDS Society Conference.
Valenti WM
AIDS Read; 2007 Sep; 17(9):435-7. PubMed ID: 17902223
[No Abstract] [Full Text] [Related]
12. [Metabolic side effects of antiretroviral therapy].
van der Valk M; Reiss P
Ned Tijdschr Geneeskd; 2008 May; 152(22):1260-4. PubMed ID: 18590059
[TBL] [Abstract][Full Text] [Related]
13. Case presentation: nephrolithiasis in a patient treated with atazanavir.
Savini C; James C; Wilson S; Martin H; Szabo S; Scotto V
J Assoc Nurses AIDS Care; 2008; 19(3):225-7. PubMed ID: 18457764
[TBL] [Abstract][Full Text] [Related]
14. Atazanavir urolithiasis.
Chang HR; Pella PM
N Engl J Med; 2006 Nov; 355(20):2158-9. PubMed ID: 17108352
[No Abstract] [Full Text] [Related]
15. Lipoprotein(a) in patients initiating antiretroviral therapy.
Mauss S; Berger F; Schmutz G; Henke J; Richter WO
HIV Med; 2008 Jul; 9(6):415-20. PubMed ID: 18459949
[TBL] [Abstract][Full Text] [Related]
16. Atazanavir: new indication. First-line treatment: fewer gastrointestinal disorders but more cases of jaundice and a risk of torsades de pointes.
Prescrire Int; 2009 Jun; 18(101):104. PubMed ID: 19637415
[TBL] [Abstract][Full Text] [Related]
17. The long-term consequences of antiretroviral therapy: a review.
Boyd M; Reiss P
J HIV Ther; 2006 Jun; 11(2):26-35. PubMed ID: 16981593
[No Abstract] [Full Text] [Related]
18. Impact of atazanavir-based HAART regimen on the carotid intima-media thickness of HIV-infected persons: a comparative prospective cohort.
de Saint-Martin L; Bressollette L; Perfezou P; Bellein V; Ansart S; Vallet S; Pasquier E
AIDS; 2010 Nov; 24(18):2797-801. PubMed ID: 21063175
[TBL] [Abstract][Full Text] [Related]
19. Urolithiasis in HIV-positive patients treated with atazanavir.
Couzigou C; Daudon M; Meynard JL; Borsa-Lebas F; Higueret D; Escaut L; Zucman D; Liotier JY; Quencez JL; Asselah K; May T; Neau D; Vittecoq D
Clin Infect Dis; 2007 Oct; 45(8):e105-8. PubMed ID: 17879904
[TBL] [Abstract][Full Text] [Related]
20. Association between atazanavir plasma levels and renal function in HIV-positive individuals on antiretroviral therapy with undetectable viral load.
Luz AJ; Poeta J; Linden R; Antunes MV; Caminha LI; Callegari-Jacques SM; Sprinz E
Int J Antimicrob Agents; 2013 May; 41(5):497-8. PubMed ID: 23453620
[No Abstract] [Full Text] [Related]
[Next] [New Search]
